Theromycin-2
Isoform of theromycin — leech-derived antimicrobial / anti-inflammatory peptide.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Isoform of theromycin — leech-derived antimicrobial / anti-inflammatory peptide.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
Theromycin-2 is documented mechanistically only; no human evidence. In vitro activity does NOT establish clinical antimicrobial efficacy, and no FDA-approved derivative exists.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 8,500 Da
- Source species
- Theromyzon tessulatum
- Discovered
- 2014
Biological Targets
- → bacterial cell membranes
- → innate immune signaling
Key Citations
- Liu Z et al. (2019), Parasit Vectors
External Resources
Related Antimicrobial Compounds
Theromacin
Antimicrobial peptide active against Gram-negative bacteria — innate immunity of leech.
Theromyzin
Antimicrobial peptide; structural analogue of mammalian defensin family.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.